Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) Assets Average (2023 - 2025)

Compass Therapeutics' Assets Average history spans 3 years, with the latest figure at $225.4 million for Q4 2025.

  • For Q4 2025, Assets Average rose 55.7% year-over-year to $225.4 million; the TTM value through Dec 2025 reached $225.4 million, up 55.7%, while the annual FY2025 figure was $180.0 million, 21.1% up from the prior year.
  • Assets Average for Q4 2025 was $225.4 million at Compass Therapeutics, up from $174.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $225.4 million in Q4 2025 and bottomed at $124.1 million in Q2 2025.
  • The 3-year median for Assets Average is $159.0 million (2024), against an average of $163.2 million.
  • The largest YoY upside for Assets Average was 55.7% in 2025 against a maximum downside of 21.66% in 2025.
  • A 3-year view of Assets Average shows it stood at $163.5 million in 2023, then fell by 11.43% to $144.8 million in 2024, then surged by 55.7% to $225.4 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Assets Average are $225.4 million (Q4 2025), $174.0 million (Q3 2025), and $124.1 million (Q2 2025).